N
Naoya Hashimoto
Researcher at Kyoto Prefectural University of Medicine
Publications - 153
Citations - 4232
Naoya Hashimoto is an academic researcher from Kyoto Prefectural University of Medicine. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 32, co-authored 140 publications receiving 3506 citations. Previous affiliations of Naoya Hashimoto include University of Tokyo & Osaka University.
Papers
More filters
Journal ArticleDOI
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
Hideho Okada,Michael Weller,Raymond Y. Huang,Gaetano Finocchiaro,Mark R. Gilbert,Wolfgang Wick,Benjamin M. Ellingson,Naoya Hashimoto,Ian F. Pollack,Alba A. Brandes,Enrico Franceschi,Christel Herold-Mende,Lakshmi Nayak,Ashok Panigrahy,Whitney B. Pope,Robert M. Prins,John H. Sampson,Patrick Y. Wen,David A. Reardon +18 more
TL;DR: Immunotherapy Response Assessment for Neuro-Oncology (iRANO) criteria based on guidance for the determination of tumour progression outlined by the immune-related response criteria and the RANO working group are described.
Journal ArticleDOI
Fiber-tracking does not accurately estimate size of fiber bundle in pathological condition: initial neurosurgical experience using neuronavigation and subcortical white matter stimulation
Manabu Kinoshita,Kei Yamada,Naoya Hashimoto,Amami Kato,Shuichi Izumoto,Takahito Baba,Motohiko Maruno,Tsunehiko Nishimura,Toshiki Yoshimine +8 more
TL;DR: A preliminary validation of tractography in human subjects harboring brain tumors is presented by comparing the results produced by neuronavigation and electrical white matter stimulation in two patients with gliomas in the eloquent area.
Journal ArticleDOI
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
Eric M. Thompson,Eric M. Thompson,Thomas Hielscher,Eric Bouffet,Marc Remke,Betty Luu,Sridharan Gururangan,Roger E. McLendon,Darell D. Bigner,Eric S. Lipp,Sébastien Perreault,Yoon Jae Cho,Gerald A. Grant,Gerald A. Grant,Seung-Ki Kim,Ji Yeoun Lee,Amulya A. Nageswara Rao,Caterina Giannini,Kay Ka Wai Li,Ho Keung Ng,Yu Yao,Toshihiro Kumabe,Teiji Tominaga,Wiesława Grajkowska,Marta Perek-Polnik,David C.Y. Low,Wan Tew Seow,Kenneth Tou En Chang,Jaume Mora,Ian F. Pollack,Ronald L. Hamilton,Sarah Leary,Andrew S. Moore,Andrew S. Moore,Wendy J. Ingram,Andrew R. Hallahan,Andrew R. Hallahan,Anne Jouvet,Michelle Fèvre-Montange,Alexandre Vasiljevic,Cécile Faure-Conter,Tomoko Shofuda,Naoki Kagawa,Naoya Hashimoto,Nada Jabado,Alexander G. Weil,Tenzin Gayden,Takafumi Wataya,Tarek Shalaby,Michael A. Grotzer,Karel Zitterbart,Jaroslav Sterba,Leos Kren,Tibor Hortobágyi,Almos Klekner,Bognár László,Tímea Pócza,Peter Hauser,Ulrich Schüller,Shin Jung,Woo Youl Jang,Pim J. French,Johan M. Kros,Marie Lise C. van Veelen,Luca Massimi,Jeffrey R. Leonard,Joshua B. Rubin,Rajeev Vibhakar,Lola B. Chambless,Michael K. Cooper,Reid C. Thompson,Claudia C. Faria,Alice Carvalho,Sofia Nunes,José Pimentel,Xing Fan,Karin M. Muraszko,Enrique López-Aguilar,David Lyden,Livia Garzia,David Shih,Noriyuki Kijima,Christian Schneider,Jennifer Adamski,Paul A. Northcott,Marcel Kool,David T.W. Jones,Jennifer A. Chan,Ana Nikolic,Maria Luisa Garrè,Erwin G. Van Meir,Satoru Osuka,Jeffrey J. Olson,Arman Jahangiri,Brandyn A. Castro,Nalin Gupta,William A. Weiss,Iska Moxon-Emre,Donald J. Mabbott,Alvaro Lassaletta,Cynthia Hawkins,Uri Tabori,James M. Drake,Abhaya V. Kulkarni,Peter B. Dirks,James T. Rutka,Andrey Korshunov,Stefan M. Pfister,Stefan M. Pfister,Roger J. Packer,Vijay Ramaswamy,Michael D. Taylor +111 more
TL;DR: A re-evaluation of the long-term implications of intensified craniospinal irradiation in children with small residual portions of medulloblastoma is suggested as the marked benefit of EOR in the overall cohort was greatly attenuated after including molecular subgroup in the multivariable analysis.
Journal ArticleDOI
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Shuichi Izumoto,Akihiro Tsuboi,Yoshihiro Oka,Tsuyoshi Suzuki,Tetsuo Hashiba,Naoki Kagawa,Naoya Hashimoto,Motohiko Maruno,Olga A. Elisseeva,Toshiaki Shirakata,Manabu Kawakami,Yusuke Oji,Sumiyuki Nishida,Satoshi Ohno,Ichiro Kawase,Jun Hatazawa,Shin-ichi Nakatsuka,Katsuyuki Aozasa,Satoshi Morita,Junichi Sakamoto,Haruo Sugiyama,Toshiki Yoshimine +21 more
TL;DR: Although a small uncontrolled nonrandomized trial, this study showed that WT1 vaccine therapy for patients with WT1/HLA-A*2402-positive recurrent GBM was safe and produced a clinical response.
Journal ArticleDOI
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
Hideyuki Arita,Hideyuki Arita,Kai Yamasaki,Yuko Matsushita,Taishi Nakamura,Taishi Nakamura,Asanao Shimokawa,Hirokazu Takami,Hirokazu Takami,Shota Tanaka,Akitake Mukasa,Mitsuaki Shirahata,Saki Shimizu,Kaori Suzuki,Kuniaki Saito,Keiichi Kobayashi,Fumi Higuchi,Takeo Uzuka,Ryohei Otani,Kaoru Tamura,Kazutaka Sumita,Makoto Ohno,Yasuji Miyakita,Naoki Kagawa,Naoya Hashimoto,Ryusuke Hatae,Koji Yoshimoto,Naoki Shinojima,Hideo Nakamura,Yonehiro Kanemura,Yoshiko Okita,Manabu Kinoshita,Kenichi Ishibashi,Tomoko Shofuda,Yoshinori Kodama,Kanji Mori,Yusuke Tomogane,Junya Fukai,Koji Fujita,Yuzo Terakawa,Naohiro Tsuyuguchi,Shusuke Moriuchi,Masahiro Nonaka,Hiroyoshi Suzuki,Makoto Shibuya,Taketoshi Maehara,Nobuhito Saito,Motoo Nagane,Nobutaka Kawahara,Keisuke Ueki,Toshiki Yoshimine,Etsuo Miyaoka,Ryo Nishikawa,Takashi Komori,Yoshitaka Narita,Koichi Ichimura +55 more
TL;DR: The findings suggest that a combination of IDH, TERT, and MGMT refines the classification of grade II-IV diffuse gliomas, and patients with TERT mutant-MGMT unmethylated GBM have the poorest prognosis.